John T. Cavan, CFO at ContraVir Pharmaceuticals, Inc. (CTRV), bought 20,000 shares at $0.65 ($13K) on 2017-06-20, disclosed to the SEC on 2017-06-22.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |